PDZD2
protein-codingPDZ domain containing 2, the group of PDZ domain containing
Gene summary
The protein encoded by this gene contains six PDZ domains and shares sequence similarity with pro-interleukin-16 (pro-IL-16). Like pro-IL-16, the encoded protein localizes to the endoplasmic reticulum and is thought to be cleaved by a caspase to produce a secreted peptide containing two PDZ domains. In addition, this gene is upregulated in primary prostate tumors and may be involved in the early stages of prostate tumorigenesis. [provided by RefSeq, Dec 2015]
- PDZK3
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~471.8 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
No GenCC data available for this gene.
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to PDZD2 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_178140.4. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 6 | 39 | 16 | 61 | ||
| missense | 429 | 49 | 16 | 494 | ||
| nonsense | 3 | 3 | ||||
| start loss | 0 | |||||
| frameshift | 2 | 2 | ||||
| splice donor/acceptor (+/-2bp) | 5 | 5 | ||||
| Total | 0 | 0 | 445 | 88 | 32 | 565 |
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_835260.2 | 24 | MANE Select | |
| Ensembl | ENSP00000402033.1 | 24 | MANE Select | |
| Ensembl | ENSP00000424901.1 | 1 | Standard | |
| Ensembl | ENSP00000612397.1 | 22 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Biological Process
- cell adhesion
Cellular Component
- extracellular region
- nucleus
- cytoplasm
- endoplasmic reticulum
- cell-cell junction
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000438447
- Coding exons
- 24
- Length
- 471521
- Individuals with no LoFs
- 125650
- Homozygous LoFs
- 1
- Heterozygous LoFs
- 97
- Defined
- 125748
- p
- 0.000390
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 1.69 | 1439 | 1.63e+3 | 0.882 | 0.0000968 | 18372 |
| Missense (PolyPhen) | 404 | 544.8 | 0.74155 | 6266 | ||
| Synonymous | -0.232 | 693 | 685 | 1.01 | 0.0000445 | 6023 |
| Loss of Function | 7.55 | 19 | 101 | 0.188 | 0.00000566 | 1210 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.00031 | 0.00031 | rare |
| Latino/Admixed American | 0.0011 | 0.0011 | notable |
| Ashkenazi Jewish | 0.000099 | 0.000099 | rare |
| East Asian | 0.00022 | 0.00022 | rare |
| Finnish | 0.00018 | 0.00018 | rare |
| European (Non-Finnish) | 0.00033 | 0.00031 | rare |
| South Asian | 0.00039 | 0.00036 | rare |
| Other | 0.00017 | 0.00016 | rare |
dbNSFP Gene Annotations
Source:
Recessive Scores
- pRec
- 0.162
Intolerance Scores
- LoFtool
- 0.533
- RVIS EVS
- 0.25
- RVIS percentile EVS
- 69.67
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- E
- Indispensability score
- 0.581
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |